Patient Perception, Preference and Participation
Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus

https://doi.org/10.1016/j.pec.2015.05.022Get rights and content

Highlights

  • We incorporated patients’ perspective in the design of a clinical practice guideline.

  • A multicomponent strategy for patient involvement was used.

  • Patient involvement in the CPG development contributed to the advance of Health Services toward patient-centered care.

Abstract

Objective

To incorporate patients’ perspective in the design of a clinical practice guideline (CPG) for Systemic Lupus Erythematosus in Spain.

Methods

A systematic review (SR) of literature and a Delphi-based consultation to patients were carried out.

Results

From the SR, most relevant health problems are classified as physical, psychological, familial, and socio-economic. Dissatisfaction is mainly due to unmet information needs and limited access to care. In the consultation (n = 102), most frequently reported health problems were pain, fatigue, photosensitivity, mood disorders, renal damage, poor concentration, and memory loss. Dissatisfaction with poor coordination between primary and specialized care was reported. Information to improve self-management and on alternative therapies was requested. Relevant topics from both sources were merged and discussed by the guideline development group (including a patient representative) to set the key questions underpinning the CPG.

Conclusion

Patient involvement in CPG development by a combination of methods can enhance patient-centered care by achieving clinical practice responsive to their needs.

Practice implications

Involving patients in CPG development is feasible and useful to improve the advance of Health Services toward patient-centered care. A multicomponent strategy for involvement is suggested to address the gap between the available evidence and contextual current patient needs and preferences.

Introduction

Systemic lupus erythematosus (SLE) is a complex chronic and multisystem disease in which various cell types and immunological pathways are deregulated explaining its variable clinical presentations, course, and prognosis. SLE affects over half a million people in Europe and a quarter of a million people in the USA, based on a prevalence rate of 30–50 per 100,000 [1]. Because of the systemic nature of SLE, several medical specialties are involved in the care of those affected. To reduce medical practice variations, the unwanted effects of care fragmentation, and optimizing clinical management of SLE patients, the European League Against Rheumatism (EULAR) Task Force developed in 2008 a set of 12 key evidence-based clinical recommendations to guide clinical decision making [1]. Two other guidelines for SLE were developed in 2011 [2] and 2013 [3] in Spain and Chile, respectively, with a lower degree of methodological transparency.

The complexity of SLE together with the challenge of the required clinical coordination among several medical specialties, the recent devolvement of new and expensive drugs for its treatment, the limited spectrum of clinical questions included in the EULAR recommendations, as well as the need of bringing up to date these evidence based recommendations [1], justify the decision of the Spanish Ministry of Health to support the development of a Clinical Practice Guideline (CPG) for SLE management. The CPG was commissioned to the Planning & Evaluation Unit of the Canary Islands Health Service (SESCS) as part of the Spanish Network of Agencies for Health Technology Assessment in the National Health System.

According to the 2011 definition developed by the Institute of Medicine of the USA, CPGs are statements that include recommendations intended to optimize patient care that are informed by a systematic review (SR) of the evidence, and an assessment of the benefits and harms of alternative care options [4]. CPGs have the potential to facilitate decision-making, improve patient care and optimize the use of available resources. Many studies recommend active patient participation in the process of CPG development to make guidelines more patient-centered [5]. Patients can identify issues that may be overlooked by health professionals and highlight areas where the patient's perspective differs from the views of health professionals, ensuring that key issues of concern to those affected are considered. Patient engagement in CPG development could also improve its translation into clinical practice. The CPGs Program supported by the Spanish Ministry of Health (http://portal.guiasalud.es/web/guest/informacion-pacientes) promotes patient involvement in the CPG development process as a preliminary step for patient empowerment and informed decision making. Earlier, this participative and instrumental approach had been adopted by countries such as Australia, the United Kingdom, and the Netherlands among other countries [6], [7], [8], [9], [10].

This paper describes both the process used and the outcomes obtained by involving patients in the development of a CPG for SLE management from the earlier steps of identification and priority setting of topics and clinical questions that should be answered by the CPG. Patient involvement was addressed to identify the main health problems and needs of care related to SLE to warrant that the contents of the CPG are really patient-centered.

Section snippets

Methods

Three different but complementary activities were performed. First, a SR of the international literature focused on health problems and perceived health care needs by SLE patients. Second, in order to receive feedback from people living with SLE in Spain, a consultative and consensus process was carried out. Third, a patient representative was recruited for the guideline development group (GDG) from the beginning to the end of the CPG development process. This study was approved by the Ethics

Systematic review

The results of the search and the selection of studies process are shown in Fig. 1. From 980 potentially relevant references initially identified, 19 studies (involving more than 2187 participants) that met the pre-established selection criteria were finally selected [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32]. The studies, published from 1988 to 2011, were conducted across 10 countries, mainly United Kingdom, USA, Australia,

Discussion

This study describes the process of obtaining key information from SLE patients about self-perceived health problems, needs and expectations with care and the obtained outcomes to guide the design and development of a CPG for SLE in Spain. The process used three different but complementary activities: first, a SR of the international literature; second, a consultation to SLE patients in Spain; and third, the inclusion of a patients’ representative as a member of the GDG from the beginning of

Competing interest

The authors have no conflict of interest with the subject matter or materials discussed in the manuscript.

We confirm all patient/personal identifiers have been removed or disguised so the patient/person(s) described are not identifiable and cannot be identified through the details of the story.

Funding sources

This work was supported by the Ministry of Health, Social Affairs and Equality of Spain in cooperation with the Instituto de Salud Carlos III, the “Fundación Canaria de Investigación Sanitaria” (FUNCANIS) and the Spanish Network of Health Services Research for Chronic Diseases (REDISSEC), in the framework of the Spanish Network of Health Technology Assessment and Clinical Guideline Development.

Acknowledgments

We gratefully acknowledge the cooperation of Mrs. Pilar Pazos, President of the Spanish Federation of Patient Associations of Systemic Lupus Erythematosus (FELUPUS) and of all participant patients affected by SLE in Spain.

References (48)

  • Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines et al.

    Clinical Practice Guidelines We Can Trust

    (2011)
  • A. Tong et al.

    Consumer involvement in topic and outcome selection in the development of clinical practice guidelines

    Health Expect

    (2012 Dec)
  • N. Rankin et al.

    Consumer participation in the development of psychosocial clinical practice guidelines: opinions of women with breast cancer

    Eur J Cancer Care (Engl)

    (2000)
  • Health Council of the Netherlands

    From implementing to learning. The importance of a dialogue between practice and science in health care

    (2000)
  • A. Van Wersch et al.

    Involvement in the development of evidence based clinical guidelines: Practical experiences from the North of England evidence based guideline development programme

    Qual Health Care

    (2001)
  • I.D. Graham et al.

    The state of the science and art of practice guidelines development, dissemination and evaluation in Canada

    J Eval Clin Pract

    (2003)
  • H.J. Schunemann et al.

    Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement

    Health Res Policy Syst

    (2006)
  • SIGN

    Scotland: Scottish Intercollegiate Guidelines Network

    (2001–2014)
  • A.K. Ali

    Using the Delphi technique to search for empirical measures of local planning agency power

    Qual Rep

    (2005)
  • B. Bauernfeind et al.

    Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: a patient Delphi exercise

    Arthritis Care Res

    (2009)
  • S. Danoff-Burg et al.

    Unmet needs of patients with systemic lupus erythematosus

    Behav Med

    (2009)
  • E.J. Philip et al.

    Confidence in medical care linked to depression in lupus sufferers

    J Allied Health

    (2009)
  • E.J.M. Zirkee et al.

    Health care usage in Dutch systemic lupus erythematosus patients

    Lupus

    (2011)
  • J.L. Poole et al.

    Parenting: the forgotten role of women living with systemic lupus erythematosus

    Clin Rheumatol

    (2012)
  • Cited by (0)

    1

    See Appendix A for the members of the Spanish SLE CPG Development Group.

    View full text